Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Rockwell Medical (RMTI) over the last 16 years, with Q4 2024 value amounting to $475000.0.

  • Rockwell Medical's Current Deferred Revenue fell 882.92% to $475000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $475000.0, marking a year-over-year decrease of 882.92%. This contributed to the annual value of $475000.0 for FY2024, which is 882.92% down from last year.
  • Rockwell Medical's Current Deferred Revenue amounted to $475000.0 in Q4 2024, which was down 882.92% from $487000.0 recorded in Q3 2024.
  • In the past 5 years, Rockwell Medical's Current Deferred Revenue ranged from a high of $11.6 million in Q1 2020 and a low of $475000.0 during Q4 2024
  • Its 5-year average for Current Deferred Revenue is $5.7 million, with a median of $7.0 million in 2022.
  • As far as peak fluctuations go, Rockwell Medical's Current Deferred Revenue surged by 41733.45% in 2020, and later tumbled by 9207.91% in 2023.
  • Quarter analysis of 5 years shows Rockwell Medical's Current Deferred Revenue stood at $10.2 million in 2020, then dropped by 19.95% to $8.2 million in 2021, then plummeted by 46.9% to $4.3 million in 2022, then plummeted by 87.97% to $521000.0 in 2023, then decreased by 8.83% to $475000.0 in 2024.
  • Its Current Deferred Revenue was $475000.0 in Q4 2024, compared to $487000.0 in Q3 2024 and $498000.0 in Q2 2024.